Teladoc (TDOC) closed at $5.42 in the latest trading session, marking a -3.39% move from the prior day. This move lagged the S&P 500's daily loss of 1.36%. At the same time, the Dow lost 1.64%, and the tech-heavy Nasdaq lost 1.46%. Shares of the telehealth services provider witnessed a gain of 23.03% over the previous month, beating the performance of the Medical sector with its loss of 5.66%, and the S&P 500's loss of 1.76%.Investors will be eagerly watching for the performance of Teladoc in its upcoming e ...

Core Insights - Teladoc's stock closed at $5.47, down 1.8%, underperforming the S&P 500 which lost 0.08% [1] - Over the past month, Teladoc's shares gained 14.85%, outperforming the Medical sector's loss of 2.21% and the S&P 500's loss of 2.16% [1] Earnings Performance - The upcoming EPS for Teladoc is projected at -$0.3, reflecting a 57.89% decline compared to the same quarter last year [2] - Revenue is estimated at $614.34 million, indicating a 2.39% decrease from the same quarter of the previous year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are expected to be -$0.89 per share, with revenue projected at $2.52 billion, showing changes of +21.93% and -0.45% respectively from the previous year [3] - Recent analyst estimate revisions are crucial as they reflect near-term business trends, with positive revisions indicating a favorable business outlook [3] Zacks Rank and Performance - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has shown that 1 ranked stocks have an average annual return of +25% since 1988 [5] - Teladoc currently holds a Zacks Rank of 3 (Hold), with a recent 5.31% increase in the consensus EPS estimate over the last 30 days [5] Industry Insights - The Medical Services industry, part of the Medical sector, has a Zacks Industry Rank of 87, placing it in the top 36% of over 250 industries [6] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]

Group 1 - Teladoc shares increased by 5.1% to $5.57, with a notable trading volume, following a Deutsche Bank upgrade from Hold to Buy due to low valuation and plans to revamp the BetterHelp segment [1] - The stock has gained 6.4% over the past four weeks, indicating positive momentum [1] - The upcoming quarterly report is expected to show a loss of $0.31 per share, a year-over-year decline of 63.2%, with revenues projected at $614.34 million, down 2.4% from the previous year [2] Group 2 - The consensus EPS estimate for Teladoc has been revised 18% lower in the last 30 days, suggesting a negative trend in earnings estimate revisions, which typically does not lead to price appreciation [3] - Teladoc currently holds a Zacks Rank of 3 (Hold), indicating a neutral outlook [4] - In the same medical services industry, Bausch + Lomb has seen a significant EPS estimate increase of 43.5% over the past month, with a current Zacks Rank of 3 (Hold) [5]

Group 1 - The CEO of the company, Charles Divita, has a long history with Teladoc, having previously been an executive at a large health plan [1] - In 2018, the importance of Teladoc was recognized in discussions with brokers, highlighting its relevance to customer bases [1] - The company decided to roll out Teladoc services to all commercial members by the fall of 2019, prior to the pandemic [2] Group 2 - The pandemic significantly impacted the company's member engagement with Teladoc services [2]

Core Viewpoint - Deutsche Bank upgraded Teladoc Health to Buy from Hold with a price target of $11, citing attractive valuation and a credible turnaround strategy for the BetterHelp segment [1] Group 1: Valuation and Market Position - Teladoc shares are currently trading at approximately 4.2 times Deutsche Bank's 2026 EBITDA estimate, one of the lowest multiples in the firm's coverage universe [2] - Such low valuations are typically associated with companies facing existential risks, which Deutsche Bank believes does not apply to Teladoc's expanding Integrated Care segment [2] Group 2: BetterHelp Segment Strategy - The BetterHelp business has been experiencing declines, but management has introduced a strategy to stabilize and grow the segment by shifting from a cash-pay model to insurance-covered therapy services [3] - Demand for insured therapy services is increasing, as evidenced by Universal Health Services' recent acquisition of Talkspace, a competitor in the insured therapy market [4] Group 3: Potential for Value Unlocking - The acquisition of Talkspace suggests a potential upside for Teladoc's current share price, indicating a path for unlocking value in the market [4]

Summary of Teladoc Conference Call Company Overview - **Company**: Teladoc Health - **CEO**: Chuck Divita - **Industry**: Telehealth and Integrated Care Key Points CEO Tenure and Company Performance - Chuck Divita reflects on his two-year tenure, noting both strengths and challenges faced at Teladoc, emphasizing the need for increased strategic focus, operational rigor, and product innovation [4] - The company aims to strengthen its position heading into 2026, particularly focusing on BetterHelp, which constitutes about 40% of revenues [4] CFO Search - The search for a new CFO is ongoing, with a focus on finding a candidate with financial expertise and operational rigor [5] Integrated Care Business Performance - Integrated Care has shown low- to mid-single-digit growth with EBITDA margins in the low double-digit to mid-teens range [6] - The business is transitioning from a subscription-based model to a fee-for-service model, driven by market demand for visit-based arrangements [7][24] - The company has seen good underlying growth in visit revenues, particularly in chronic care, which has experienced enrollment growth [9][8] Membership and Guidance - Teladoc has approximately 100 million members, with a projected low single-digit decline in membership for the year due to external healthcare factors [10][14] - Membership has grown by about 40% since 2020, but challenges such as Medicaid redeterminations and changes in the Affordable Care Act may impact retention [15] Chronic Care Segment - Sequential growth in chronic care enrollment is expected, with opportunities for upselling and engaging new members [17][20] - The company aims to penetrate its existing member base more deeply, particularly in weight management services [21] BetterHelp Business Update - BetterHelp has faced volatility but is expected to stabilize as the company pivots towards insurance coverage, which is anticipated to drive growth [30][31] - The direct-to-consumer cash pay model has seen high drop-off rates, with over 80% of potential users not converting due to cost barriers [34] - The company expects to see increased user engagement and lifetime value as insurance coverage expands [36] Financial Guidance and Debt Management - For fiscal 2026, Teladoc anticipates revenue growth driven by insurance scaling and international growth, with projected insurance revenues of $75 million to $90 million [43] - The company plans to pay down a significant portion of its $1 billion debt due next year, leveraging existing cash and traditional term debt [51][52] Market Position and Competitive Landscape - The company views recent M&A activity in the behavioral health space as validation of the demand for virtual mental health services [39] - Teladoc has a strong market position with over 12,000 clients and a significant data advantage, which is crucial for AI deployment in healthcare [55] AI and Future Outlook - Teladoc is actively investing in AI to enhance engagement and service delivery, leveraging its extensive data to improve clinical interventions [54][56] - The company believes its deep expertise in healthcare and regulatory knowledge creates competitive moats in the telehealth industry [56] Additional Insights - The transition to visit-based revenues is seen as beneficial for service engagement, despite some initial headwinds from the subscription model [25] - The company is focused on operational efficiency and cost management to drive EBITDA results [43]

Core Viewpoint - Teladoc Health Inc. reported stronger-than-expected quarterly results, with a notable increase in sales despite a projected loss for the upcoming quarters [2][3]. Financial Performance - In the latest quarterly report, Teladoc Health posted a loss of 14 cents per share, which was better than the consensus loss of 18 cents [2]. - Sales reached $642.27 million, exceeding the expected $635.24 million, driven by a 24% increase in other revenue streams, although access fees revenue declined by 4% [2]. - For Q1 2026, Teladoc expects a loss between 35-45 cents per share and sales of $598-$620 million, compared to the consensus loss of 25 cents and sales of $633.75 million [3]. - The fiscal 2026 outlook includes a projected loss of 70 cents to $1.10 per share and sales between $2.47 billion to $2.59 billion, against the consensus of 76 cents and $2.55 billion [3]. Analyst Reactions - Deutsche Bank upgraded Teladoc from Hold to Buy, citing compelling valuation and potential exit scenarios, with a price forecast of $11 [4]. - BTIG remains cautious, maintaining a Neutral rating, highlighting concerns over the macro environment and market saturation [4]. - Oppenheimer reiterated an Outperform rating but lowered the price target from $12 to $7, while Citigroup maintained a Neutral rating with a reduced target from $9 to $6 [5]. - Other analysts, including Piper Sandler and BMO Capital, also adjusted their price targets downward while maintaining their respective ratings [5][6]. Stock Performance - Teladoc shares are currently trading 21.8% above their 20-day simple moving average (SMA) but 12.5% below their 100-day SMA, indicating short-term strength amidst long-term struggles [7]. - Over the past year, shares have decreased by 40.65% and are closer to their 52-week lows than highs [7]. - The Relative Strength Index (RSI) is at 52.22, indicating neutral territory, while the MACD shows bullish momentum at -0.1341, above its signal line [8][9]. Price Action - As of the latest publication, Teladoc shares were up 5.57% at $5.59 [10]. - Key resistance level is identified at $6.50, with key support at $5.00 [10].

Core Insights - Wall Street analysts have turned bullish on Hims & Hers (HIMS), Teladoc Health (TDOC), and Alector (ALEC) due to strategic partnerships that have reshaped their risk profiles [1][2] Company Summaries Hims & Hers Health (HIMS) - HIMS stock surged 34.47% to $22.16 after resolving a lawsuit with Novo Nordisk through a distribution partnership, with price targets set between $23 and $28 by analysts [1] - BofA upgraded HIMS from Underperform to Neutral, raising the price target from $12.50 to $23, citing the removal of legal risks [1] - Deutsche Bank maintained a Hold rating but increased the target to $28, highlighting the strategic shift away from compounded semaglutide [1][2] Teladoc Health (TDOC) - TDOC's stock is currently priced at $5.30, with Deutsche Bank upgrading it from Hold to Buy and setting a price target of $11, indicating substantial upside potential [1] - The upgrade is based on compelling valuation, a credible turnaround plan for the BetterHelp segment, and stable revenue from the Integrated Care segment, which grew 2% in Q3 2025 [1][2] - The company reported Q3 2025 revenue of $626.44 million, missing consensus estimates, with BetterHelp revenue declining 8% [1] Alector (ALEC) - ALEC's stock rose 40.38% year-to-date to $2.19, with BTIG upgrading it from Neutral to Buy and setting a price target of $6 [1] - The upgrade reflects confidence in Alector's pivot to its Alector Brain Carrier (ABC) platform following a setback in a frontotemporal dementia trial [1] - Alector reported Q4 2025 revenue of $6.24 million, significantly beating the consensus estimate of $2.11 million, and holds $256 million in cash to fund operations through 2027 [1][2]

Upgrades - TD Cowen upgraded Rivian (RIVN) to Buy from Hold with a price target of $20, up from $17, based on a detailed R2 demand analysis indicating full scale R2 demand at 212,000-335,000 units, suggesting upside to consensus forecasts for 2027 [2] - Morgan Stanley upgraded CrowdStrike (CRWV) to Overweight from Equal Weight with a price target of $510, up from $487, believing CrowdStrike is best positioned in security to outperform in the coming years, stating the platform is "most able to gain share" [2] - Deutsche Bank upgraded Teladoc (TDOC) to Buy from Hold with an $11 price target, viewing the stock's valuation as "compelling" at current share levels [2] - BofA upgraded Hims & Hers (HIMS) to Neutral from Underperform with a price target of $23, up from $12.50, noting a positive development as Novo Nordisk dropped its lawsuit, removing litigation and related credit risk [2] - Citi also upgraded Hims & Hers to Neutral from Sell with a price target of $24, up from $13.25 [2] - Rothschild & Co Redburn upgraded Intuit (INTU) to Buy from Neutral with a price target of $700, up from $670, indicating 46% upside from current levels, highlighting the resilience of QuickBooks and TurboTax applications to AI disruption risk in the enterprise software sector [2]

Financial Performance - Teladoc Health reported a quarterly loss of 14 cents per share, which was better than market estimates of a loss of 18 cents per share [1] - The company's sales for the quarter reached $642.269 million, exceeding estimates of $635.235 million [1] - For FY2026, Teladoc Health anticipates a GAAP loss in the range of $(1.10) to $(0.70), compared to market estimates of $(0.76) [1] - The company expects sales between $2.470 billion and $2.587 billion, surpassing estimates of $2.548 billion [1] Strategic Outlook - The CEO of Teladoc Health, Chuck Divita, expressed optimism about the company's progress in 2025, highlighting that consolidated revenue and adjusted EBITDA were above the midpoint of guidance ranges for the fourth quarter [2] - The company has made advancements in its product portfolio and innovation across Integrated Care and BetterHelp, positioning itself for continued momentum in 2026 [2] Market Reaction - Following the earnings report, Teladoc Health shares increased by 13.5%, trading at $5.28 [3]